Meet our clinical discovery engine

The product of over two decades of work, MolecuLern combines a deep understanding of biology and chemistry with the power of modern technology. This includes cutting-edge computational tools and machine learning AI, which are revolutionizing the drug discovery process. MolecuLern leverages these tools to streamline the traditional trial-and-error methods that have dominated the field for centuries.

Meet the humans driving innovation

Co-founders David Bearss and Hari Vankayalapati are pioneers in the field of drug discovery, each with more than 20 years of experience in small molecule drug development. Today, they are among the first to utilize computational techniques combined with wet lab ‘fingerprints’ for drug discovery. The team at MolecuLern boasts over 100 patents, filed twenty INDs, has been involved in hundreds of clinical trials, and has achieved significant exits from previous companies.

brings the advantages of HUMAN-POWERED AI to companies, chemists, and combination pioneers.

Ways to leverageinclude:

• Hit Identification/Lead Optimization
• End-to-End Full Collaboration
• Custom compound optimization
• Custom library screening
• Screen our entire physical/virtual library